Eli Lilly Shares Under Pressure Following Strategic Price Cuts
Published on 12/07/2025 at 04:02 | Redaktion boerse-global.de
Investor sentiment toward Eli Lilly turned cautious last week, with the pharmaceutical giant’s stock declining approximately 4.5% over a five-day period. The move followed the company’s announcement of significant price reductions for its weight-loss medication, Zepbound, raising questions about the impact on future profitability in a key growth segment.
In early December, Eli Lilly unveiled new pricing for single-dose vials of Zepbound through its direct-to-consumer platform, LillyDirect. The adjustments represent a substantial decrease across all dosage strengths.
The company framed the decision as a move to improve patient access. Ilya Yuffa, Executive Vice President of Lilly USA, stated that significant cost and reimbursement barriers continue to Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
